SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs acknowledged affair with an executive suspected by U.S. officials of links to Chinese intelligence, and Nvidias board investigation, have fueled concern about possible security, governance and leadership fallout; the espionage allegations remain unproven. Traders are divided between expecting further pressure if the probe raises new risks and viewing the selloff as an overreaction and a buying opportunity given Nvidias business fundamentals.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Traders are speculating that Nvidias investigation into its CEOs reported relationship with a suspected Chinese intelligence asset could drive money toward AMD and other chip rivals. Others caution that broader AI-sector volatility and data-center spending concerns remain, and debate whether AMDs sharp rebound can hold.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A strong run-up into TG Therapeutics Q3 results has focused attention on BRIUMVIs sales momentum and any update on its subcutaneous Phase 3 program. Many traders are bullish on the commercial growth and speculate about a buyout or short squeeze, while others caution that earnings expectations may already be reflected in the share price; the takeover talk remains unconfirmed.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.11892236 USD and is down -3.62 over the last 24 hours. It is currently trading on 1894 active market(s) with $1,884,610,999.15 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is drawing attention amid a sharp crypto-wide selloff, with traders linking its decline to broader market weakness and debating whether the pullback is a buying opportunity or a sign of further downside. Some blame political and regulatory uncertainty, but that remains speculation in the discussion.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,200,877.25744775. The last known price of Ethereum is 2,141.49627095 USD and is down -4.09 over the last 24 hours. It is currently trading on 14297 active market(s) with $9,084,277,576.13 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereums steep decline amid a broader crypto selloff and reported leveraged-long liquidations is driving attention; traders cite risk-off pressure and possible spillover from tech-market weakness, though the causes are debated. Bearish posts focus on weak price action and further downside, while others are buying the dip and looking for a reversal.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Bridgewater, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Attention centers on Legend Biotechs Q3 call, with CARVYKTI sales already reported and traders looking for detail on margins and the 2027 outlook. The community is largely optimistic about the drugs growth, while also watching for ASH clinical updates; speculation about promising in-vivo data or a deal remains unconfirmed.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp rebound from a severe semiconductor selloff, as dip buyers and possible short covering counter fears that AI spending and data-center expansion could slow. Traders disagree on whether the bounce marks a bottom or is only a temporary relief rally, with uncertainty around Nvidia and the broader AI trade adding to volatility in the leveraged fund.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Attention centers on povetacicepts upcoming FDA decision for IgA nephropathy, with traders pointing to positive Phase 3 RAINIER results and debating the drugs potential as a new growth engine beyond cystic fibrosis. Recent quarterly results and raised revenue guidance drew mixed reactions, with some investors focused on the strong business performance and others concerned about the earnings shortfall and valuation.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Virs Phase 3 ECLIPSE-1 hepatitis delta combination met its endpoints, with strong viral suppression results drawing attention and reinforcing the communitys view that the treatment could be best-in-class. Traders are broadly bullish, but debate whether the data make a buyout more likely or whether Virs hepatitis and oncology pipelines have greater value if the company remains independent while awaiting further trial results.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit is drawing attention around the FDAs review of ivonescimab plus chemotherapy for EGFR-mutated lung cancer. Traders are split: the Phase 3 trial met its progression-free-survival goal, but the primary overall-survival analysis missed statistical significance, leaving approval uncertain; some bulls point to later survival data and AstraZenecas investment as support for the drugs prospects.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
